Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndrome
- Conditions
- Healthy subjects, Parkinson's disease patients and Parkinson's syndrome patients
- Registration Number
- JPRN-UMIN000016485
- Lead Sponsor
- Institute of Biomedical Research and Innovation
- Brief Summary
Published in Ann Nucl Med 2017; 31:163-171,
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
Subjects who consciousness is not clear Subjects with cerebrovascular disorder Subjects with cardiac dysfunction Subjects with QT prolongation and ventricular arrhythmias on the electrocardiogram Subjects with liver and kidney failure Subjects with gastric ulcer and duodenal ulcer Subjects with diabetes Subjects with serious lung disease, bronchial asthma and endocrine disease Subjects with angle-closure glaucoma and chronic open-angle glaucoma Subjects who are psychiatric symptoms such as suicidal tendencies Subjects who are taking non-selective monoamine oxidase inhibitors Subjects who suffer from the symptomatic parkinsonism by clear organic cause Subjects who have the history of drug allergy Subjects who it is difficult to skip Parkinson treatment medicine from the day before Subjects with rhabdomyolysis Subjects with malignant syndrome Subjects with pheochromocytoma Subjects with prolactin-secreting pituitary tumor Subjects who are dehydration and malnutrition state Subjects Who exhibit a strong response to drink Subjects who are drug dependence, alcohol dependence Subjects who have participated in clinical research within the past 3 months Subjects who reserchers judged as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method